ArticleCancer medicine2025
Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum-Based Doublet Chemotherapy for Extensive-Stage Small-Cell Lung Cancer Patients With Eastern Cooperative Oncology Group-Performance Status 2-3: A Single-Institution Retrospective Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of small-cell lung cancer (SCLC) remains poor, particularly in patients with extensive-stage SCLC. The IMpower133 and CASPIAN trials revealed the efficacy of immune checkpoint inhibitors (ICIs) in extensive-stage SCLC patients with good performance status (PS). The aim of this study was to investigate the efficacy of ICIs in patients with poor PS. PATIENTS AND
methodsPatients with extensive-stage SCLC who visited Saitama Medical Center, Saitama Medical University (Kawagoe, Japan) (September 2019-December 2022) were enrolled and followed up until February 2024. Objective response rate (ORR) and overall survival (OS) were compared between patients who received platinum-based doublet chemotherapy with an ICI (atezolizumab or durvalumab; ICI group) and those treated with platinum-based doublet chemotherapy alone (non-ICI group). Results were stratified by the Eastern Cooperative Oncology Group performance status (ECOG-PS) (i.e., 0-1 and 2-3).
resultsA total of 74 patients were included in the study (median OS: 327 days). In patients with ECOG-PS 0-1, ORR was 76.5% and 56.5% in the ICI group (n = 17) and non-ICI group (n = 23), respectively; OS was 406 and 379 days, respectively. In patients with ECOG-PS 2-3, ORR was 93.3% and 56.3% in the ICI group (n = 15) and non-ICI group (n = 16), respectively; OS was 446 days and 169 days, respectively. This evidence indicates that the addition of an ICI significantly improved OS (p = 0.00661) and enhanced ORR.
conclusionIn patients with extensive-stage SCLC and ECOG-PS 2-3, the addition of atezolizumab or durvalumab to platinum-doublet chemotherapies improved the ORR, resulting in a better prognosis. These findings suggest that chemoimmunotherapy may be a feasible treatment option beyond the ideal clinical trial populations, addressing an unmet clinical need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.